<DOC>
	<DOCNO>NCT00731848</DOCNO>
	<brief_summary>This study open-label extension double-blind GUP-0205-1 double-blind extension GUP-0205-1XX study . High concentration anti-oxidants pomegranate seed present potential strategy delay clinical prostate cancer progression prolong interval treatment failure hormonal ablation . Eligible male subject previously assign placebo group double-blind core study double-blind extension study diagnose disease progression placebo treatment . Upon satisfy entry criterion , subject receive open-label pomegranate extract 48 month absence disease progression intolerable toxicity .</brief_summary>
	<brief_title>Open-label Extension Study Effects Pomegranate Extract Rising PSA After Primary Therapy Prostate Cancer</brief_title>
	<detailed_description>This study open-label extension double-blind GUP-0205-1 double-blind extension GUP-0205-1XX study . Eligible male subject , i.e. , men rise PSA level follow primary therapy localize prostate cancer , previously assign placebo group double-blind study double-blind extension diagnose disease progression placebo treatment . Upon satisfy entry criterion , subject receive open-label pomegranate extract 48 month absence disease progression intolerable toxicity .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Documented disease progression placebo GUP02051 GUP02051XX study ( ≥100 % increase baseline serum PSA minimum increase 1.0 ng/mL . Willingness ability sign inform consent document . Agreement complete abstinence commercially available pomegranate product course study . Use dietary/herbal supplement ( e.g. , saw palmetto , selenium , etc ) acceptable provide dose stable least 2 month prior screen subject agrees change/stop course study . Performance status 0 1 ECOG scale time entry extension Study . Significant concomitant medical psychiatric condition , opinion investigator , would make subject poor protocol candidate . Hormonal therapy , exception neoadjuvant androgen deprivation therapy ( ADT ) prior concurrent primary therapy . Subjects underwent neoadjuvant ADT serum testosterone ≤150 ng/mL study entry . Concomitant antecedent hormonal therapy rise serum PSA initial therapy prostate cancer . Subjects unable unwilling comply protocol requirement . Prior treatment experimental drug , high dose steroid , cancer treatment within 4 week prior first dose study product duration study . Serum PSA &gt; 7.0 ng/mL ( assessed termination doubleblind study ET doubleblind extension GUP02051XX ) ; PSA level , subject exclude determined investigator subject 's continued participation would best interest ) . Serum PSA double time &lt; 13 week ( assessed termination doubleblind study ET doubleblind extension GUP02051XX ) ) . Evidence metastatic disease physical examination CT bone scan . Use finasteride , dutasteride point since primary therapy study . Clinically significant abnormal laboratory value great 2 time upper limit normal ( &gt; 2XULN ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate-specific antigen</keyword>
	<keyword>PSA</keyword>
</DOC>